• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr Mike Lattanzi: Precision Oncology Options and Increasing Rates of Prostate Cancer

Video

Mike Lattanzi, MD, genitourinary medical oncologist, Texas Oncology, discusses the importance of keeping pace with precision oncology options as rates for prostate cancer increase.

Mike Lattanzi, MD, genitourinary medical oncologist at Texas Oncology, discusses the use of next-generation sequencing when treating an increasing number of patients with genitourinary diseases.

Transcript

Is payer coverage for genomic testing keeping pace with the precision oncology options in genitourinary disease?

I'm fortunate enough to be able to send next-generation sequencing on virtually all of my patients with metastatic disease. And I routinely send both tissue-based as well as liquid cell-free DNA next-generation sequencing for all patients with metastatic GU [genitourinary] cancers.

The most recent annual report on cancer statistics from the American Cancer Society showed a rise in prostate cancer after years of decline. What are your thoughts on why prostate cancer is increasing?

There's recently been an increase in the incidence of prostate cancer diagnoses as well as a trend toward later-stage diagnoses, which a lot of us feel is due to diminished screening during the COVID-19 pandemic. So, these data are just a reminder to always be screening patients in a guideline-appropriate fashion moving forward.

Related Videos
Debra Boyer, MD, MHPE, ATSF.
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Plasminogen is vital in the body's coagulation process and breaking down clots | image credit: peterschreiber.media - stock.adobe.com
ISPOR 2024 Recap
Chris Pagnani, MD, PC
Screenshot of Stephen Freedland, MD, during a video interview
Phaedra Corso, PhD, associate vice president for research at Indiana University
Julie Patterson, PharmD, PhD
William Padula, PhD, MSc, MS, assistant professor of pharmaceutical and health economics, University of California Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences
Michael Morse, MD, Duke Cancer Center
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.